Assessment of the prognostic value of TPM4 expression in glioma patients subgrouped by histological type, sex, IDH mutation status, WHO grade, chromosome 1p/19q codeletion, and patient age showed that high expression of TPM4 was associated with poorer prognosis in all of these groups (Fig. 4A–C). Here, TPM4 is linked to central nervous system cancer.